AGREEMENTAgreement • May 16th, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • February 25th, 2014 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTBaker Julian • August 15th, 2006 • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Seattle Genetics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • June 3rd, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • February 21st, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • March 10th, 2014 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • May 18th, 2012 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • February 14th, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
EXHIBIT 1Baker Julian • October 13th, 2005 • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.01 par value, of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • April 23rd, 2012 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.01 par value, of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
Incyte CorporationLetter Agreement • November 15th, 2013 • Baker Julian • Services-commercial physical & biological research
By entering into this letter agreement (this “Agreement”), each party signing this Agreement under the heading “HOLDER” on the signature page hereto (each a “Holder” and, collectively, the “Holders”) and Incyte Corporation, a Delaware corporation (the “Company”) irrevocably agree as follows:
January 4, 2012Underwriting Agreement • January 11th, 2012 • Baker Julian • Biological products, (no disgnostic substances)
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and J.P. Morgan Securities LLC (“J.P. Morgan”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Synageva BioPharma Corp., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley and J.P. Morgan (the “Underwriters”), of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).
AGREEMENTAgreement • January 8th, 2008 • Baker Julian • Services-commercial physical & biological research
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Incyte Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • August 2nd, 2013 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • September 27th, 2013 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the common stock, $0.001 par value, of Synageva BioPharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • June 5th, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • May 14th, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • January 14th, 2008 • Baker Julian • Services-commercial physical & biological research
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Incyte Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • November 9th, 2011 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Synageva BioPharma Corp, Inc. and suchother amendments as may be filed by them hereafter, are being filed with the Securities and Exchange Commission on behalf of each of them.
VOTING AGREEMENTVoting Agreement • April 23rd, 2012 • Baker Julian • Pharmaceutical preparations • Delaware
This Voting Agreement (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc. (“Parent”) and the undersigned stockholder (the “Stockholder”) of Ardea BioSciences, Inc., a Delaware corporation (the “Company”).
AGREEMENTAgreement • June 2nd, 2009 • Baker Julian • Biological products, (no disgnostic substances)
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • September 29th, 2006 • Baker Julian • Pharmaceutical preparations • British Columbia
NOW THEREFORE this Agreement witnesses that, in consideration of the premises and the covenants and agreements herein contained, the parties hereto agree as follows:
LOCK-UP LETTER July 9, 2012Lock-Up Letter • July 20th, 2012 • Baker Julian • Biological products, (no disgnostic substances)
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Synageva BioPharma Corp., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley (the “Underwriter”), of shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).
PROCEEDS AGREEMENTProceeds Agreement • May 19th, 2016 • Baker Julian • Services-medical laboratories • New York
WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Schedule A;
PROCEEDS AGREEMENTProceeds Agreement • March 17th, 2016 • Baker Julian • Services-commercial physical & biological research • New York
WHEREAS, the Agent, in his capacity as a director of Incyte Corporation (the “Company”), received non-transferable options (the “Options”) to purchase 20,000 shares of the Company common stock (the “Stock”) according to the below Schedule A;
AGREEMENTAgreement • August 8th, 2007 • Baker Julian • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.01 par value, of Biocryst Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTBaker Julian • January 17th, 2006 • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, no par value, of Anormed, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • December 12th, 2007 • Baker Julian • Services-commercial physical & biological research
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Incyte Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • May 24th, 2013 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LPLoan Agreement • May 19th, 2016 • Baker Julian • Services-medical laboratories • New York
For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., 667, L.P., and 14159, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interest payable through the Due Date at a rate of 2.24% annually.
AGREEMENTAgreement • December 23rd, 2008 • Baker Julian • Services-commercial physical & biological research
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Incyte Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • October 1st, 2009 • Baker Julian • Services-commercial physical & biological research
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, each of the undersigned hereby agrees that this Amendment No. 11 to Schedule 13D relating to the Common Stock, $0.001 par value, of Incyte Corporation is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • June 11th, 2008 • Baker Julian • Services-medical laboratories
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
JOINT FILING AGREEMENTJoint Filing Agreement • July 19th, 2012 • Baker Julian
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Synageva Biopharma Corp. is being filed with the Securities and Exchange Commission on behalf of each of them.
AGREEMENTAgreement • February 13th, 2006 • Baker Julian • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, no par value, of Anormed Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
